The European Union does not expect US pharmaceutical giant Johnson & Johnson to meet its goal of delivering 55 million Covid-19 vaccines in the second quarter of 2021, after manufacturing issues arose, an EU commission spokesperson said on Wednesday (16 June).
The US Food and Drug Administration said last week that several batches produced at the Baltimore-based Emergent BioSolutions factory had been contaminated with materials for another vaccine manufactured at the same site, and must...
Back our independent journalism by becoming a supporting member
Already a member? Login hereElena is EUobserver's Managing Editor. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.
Elena is EUobserver's Managing Editor. She is from Spain and has studied journalism and new media in Spanish and Belgian universities. Previously she worked on European affairs at VoteWatch Europe and the Spanish news agency EFE.